CAS: 497223-25-3; (S)-8-(4-(2-Butoxyethoxy)Phenyl)-1-Isobutyl-N-(4-(((1-Propyl-1H-Imidazol-5-yl)Methyl)Sulfinyl)Phenyl)-1,2,3,4-Tetrahydrobenzo[b]Azocine-5-Carboxamide

该化合物是一种小分子,对CCR5和CCR2化学受体具有对抗作用,它们参与炎症过程和艾滋病毒感染;主要调查其在治疗艾滋病毒和非酒精类类肝炎(NASH)方面的潜在治疗应用;该院落展示了独特的行动机制,阻止艾滋病毒进入宿主细胞,并调控与肝炎有关的免疫反应;环球病的特点是其相对较低的分子重量和具体的结构特征,从而能够使其具有受体约束的能力;在临床前科和临床研究中,该院落显示出减少肝炎和纤维化的前景,使其成为对肝病进一步研究的候选;其药性肿瘤特征表明,它可以口服,并在各种临床试验中进行了安全性和有效性评估;与任何调查药物一样,正在进行的研究对于充分了解其治疗潜力和长期影响至关重要.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2024400552-A1
    优先权日:2016-11-11
    标题 :Heterocyclic modulators of lipid synthesis
    发明人:BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
    权利人:SAGIMET BIOSCIENCES INC
    摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

    专利号:US-11622968-B2
    优先权日:2011-03-08
    标 题:Heterocyclic modulators of lipid synthesis
    发明人:BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
    权利人:SAGIMET BIOSCIENCES INC
    摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

    专利号:US-12358903-B2
    优先权日:2016-06-13
    标题 :FXR (NR1H4) modulating compounds
    发明人:BLOMGREN PETER A; CURRIE KEVIN S; FARAND JULIE; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
    权利人:GILEAD SCIENCES INC
    摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

    专利号:US-11739065-B2
    优先权日:2016-06-13
    标题 :FXR (NR1H4) modulating compounds
    发明人:BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
    权利人:GILEAD SCIENCES INC
    摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

    专利号:WO-2025080818-A1
    优先权日:2023-10-10
    标 题:Combinations of fasn inhibitors and glp-1 agonists for liver diseases
    发明人:O'FARRELL ANNE-MARIE; TSAI WEN-WEI
    权利人:SAGIMET BIOSCIENCES INC
    摘要:Combinations of fatty acid synthesis (FASN) inhibitors and glucagon-like peptide-1 (GLP-1) agonists for treating NAFLD/MAFLD, NASH/MASH, liver fibrosis and/or liver cirrhosis.

    专利号:TW-585869-B
    优先权日:1996-11-15
    标题 :Synthesis of ruthenium or osmium metathesis catalysts

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018 Mar;27(3):301-311. doi: 10.1080/13543784.2018.1442436. Epub 2018 Feb 22. 53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16.
    3: Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020 Sep;72(3):892-905. doi: 10.1002/hep.31108. Epub 2020 Jul 21.
    15:3997-4009. doi: 10.2147/DDDT.S315724.

    合成参考文献


    参考文献:10.1128/aac.49.11.4584-4591.2005
    摘要:Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y. TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans. Antimicrob Agents Chemother. 2005 Nov;49(11):4584–91. doi: 10.1128/aac.49.11.4584-4591.2005.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知